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HER2+ breast cancer is one of the most aggressive forms of breast cancer. The new polymalic acid-based mini nanodrug copolymers are
synthesized and specifically characterized to inhibit growth of HER2+ breast cancer. These mini nanodrugs are highly effective and in the
clinic may substitute for trastuzumab (the marketed therapeutic antibody) and antibody-targeted nanobiocongugates. Novel mini nanodrugs
are designed to have slender shape and small size. HER2+ cells were recognized by the polymer-attached trastuzumab-mimetic 12-mer
peptide. Synthesis of the nascent cell-transmembrane HER2/neu receptors by HER2+ cells was inhibited by antisense oligonucleotides that
prevented cancer cell proliferation and significantly reduced tumor size by more than 15 times vs. untreated control or PBS-treated group.
We emphasize that the shape and size of mini nanodrugs can enhance penetration of multiple bio-barriers to facilitate highly effective
treatment. Replacement of trastuzumab by the mimetic peptide favors reduced production costs and technical efforts, and a negligible
immune response.
© 2016 Published by Elsevier Inc.
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Abbreviations: AHNP, anti-HER2/neu peptide; Alexa, Alexa Fluor 680 (fluorescent dye); anti-TfR, anti-transferrin receptor; AON, antisense
oligonucleotide; ATCC, American Type Culture Collection; BT474, HER2 overexpressing human breast cancer cell line; DCC, N,N
′-dicyclohexylcarbodiimide; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; EGFR, epidermal growth factor receptor; FBS, fetal bovine
serum; HER2, neu, c-erbB2, members of the epidermal growth factor HER family of tyrosine kinase receptors; SEC-HPLC, size exclusion chromatography-high
performance liquid chromatography; IV, intravenous; LLL, leucyl-N-leucyl-N-leucine; Mal, maleimide; MEA, 2-mercapto-1-ethylamine; NHS,
N-hydroxysuccinimide ester; No drug, P/LLL(40%)/PEG3400-starPEG(PEG200-AHNP)2 (2%); PBS, phosphate-buffered saline; PEG200, PEG2000,
PEG3400, polyethylene glycol (PEG) with molecular weights of 200, 2000, and 3400, respectively; PDP, 3-(2-pyridyldithio)-propionic acid; PMLA or P,
poly(β-L-malic acid); SPR, surface plasmon resonance; starPEG, 8-arm PEG carboxylic acid (−COOH); TEM, transmission electron microscopy; TLC, thin
layer chromatography; RU, resonance unit.
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The HER2 protein of the epidermal growth factor receptor
(EGFR) family plays a key role in aggressive human breast
cancer. The humanized anti-HER2/neu monoclonal antibody
trastuzumab (Herceptin; Genentech, Inc.) is used alone or in
combination with other agents for the treatment of patients.1–3 In
mouse models, we have shown that the efficacy for the treatment
of human HER2-positive breast cancer with free trastuzumab
alone could be significantly increased when the antibody was
co-liganded with poly(β-Lrange-malic acid and an antisense
oligonucleotide (AON) targeting HER2-mRNA.4,5 After the
successful use of trastuzumab with affinity in the low nanomolar
range,6,7 peptides with affinities in the high nanomolar region7–9
and affibodies with affinities in the picomolar to low nanomolar
regions have been developed and successfully used for tumor
imaging.10,11 Examples of targeted therapy using anti-HER2/neu
peptide (AHNP) or affibodies alone or in combination with other
molecules have demonstrated variable degrees of tumor-specific
growth inhibition.12–14
Although tissue penetration is a multifactorial issue in drug
delivery,14–15 an emerging concept suggests that targeted “mini”
nanodrugs with a slim shape (i.e., polymeric nanoconjugates
with hydrodynamic diameter ~ 8 nm small but larger than
~5 nm, the cut-off for fast renal clearance16) are desirable for
achieving deep tissue penetration because they encounter the
fewest diffusional barriers. Polymeric nanoconjugates based on
70 to 100 kDa poly (β-L malic acid) (PMLA) have been
successfully used in delivery of drugs to brain and breast tumors.
However, their sizes cannot be reduced below diameters of 15 to
25 nm due to the sizes of the antibodies that are attached for
specific targeting.4,5 On the basis of hydrodynamic consider-
ations, elongated nanomolecules would be superior in quickly
“shuffling” their way through dense areas (e.g., intercellular
matrix) in comparison to spherically shaped molecules of similar
size. Small particles move faster than large ones, as can be
routinely observed under the microscope in the type of
movement known as Brownian motion.
In addition to improving mobility, other aspects favor mini
nanodrugs. Examples include the replacement of antibodies that
could result in reduced effort and cost for manufacturing,
lyophilization for packaging, smaller infusion volume needed for
cancer treatment, low if any immunogenicity, and stability. The
combination of trastuzumab with PMLA has enabled a novel,
unprecedentedly effective treatment of HER2-positive breast
cancer.4,5 The biodegradable, nontoxic, and non-immunogenic
platform of PMLA offers a multitude of pendant carboxylic
groups that can be functionalized with (pro)drug(s), prodrug-ac-
tivating groups, targeting peptide(s), protective polyethylene
glycol (PEG), membrane-destabilizing peptides, and dyes for
imaging.4,5,18–20
Our design of a novel mini nanodrug follows the previous
design involving a HER2-mRNA annealing Morpholino AON
5′-CATGGTGCTCACTGCGGCTCCGGC-NH2–3′,
4 but re-
duces the molecular weight of PMLA to 50 kDa and replaces
trastuzumab by AHNP, the 12 amino acid exocyclic mimetic
peptide NH2-YCDGFYACYMDV-NH2 (analogue 3).
8 The AON
is delivered as a prodrug while attached to PMLA. Drug activation
occurs in the recipient cancer cell when the disulfide linkage with
the polymer is reductively cleaved by cytoplasmic glutathione.TE
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Methods
Reagents
Polymalic acid with molecular weight 50,000 (SEC-HPLC/
polystyrene sulfonate standards, polydispersity 1.2) was isolated
from the culture supernatant of Physarum polycephalum
M3CVII and purified to homogeneity as previously described.19
A Morpholino AON that targeted HER2-mRNA (3′-amine
modified) was synthesized by Gene Tools (Philomath, OR,
USA). AHNP targeting HER2, NH2-PEG200-AHNP, and
NH2-PEG2000-AHNP were custom made by AnaSpec, Inc.
(Fremont, CA, USA). Eight-arm PEG carboxylic acid (−COOH)
(starPEG, 10 kDa) was obtained from Creative PEGWorks
(Chapel Hill, NC, USA). NH2-PEG3400-Mal was obtained from
JenKem Technology USA Inc. (Plano, TX, USA). Alexa Fluor
680 NHS ester and Alexa Fluor 680 C2 maleimide were obtained
from Thermo Fisher Scientific, Inc. (Waltham, MA, USA).
PD-10 columns were obtained from GE Healthcare (Uppsala,
Sweden).
Cell lines
HER2-positive BT474 human breast cancer cells were
obtained from American Type Culture Collection (ATCC;
Manassas, VA, USA) and subcultured in Hybri-Care medium
(ATCC) with 10% FBS at 37 °C in a humidified incubator, and
passaged every 4-5 days. The HER2-negative MDA-MB-468
cell line was obtained from ATCC and used as a control.4
Synthesis of starPEG(PEG200-AHNP)2-8, P/LLL(40%)/
PEG3400-starPEG(PEG200-AHNP)2(2%), and P/LLL(40%)/
PEG3400-starPEG(PEG200-AHNP)2(2%)AON(1.5%)
Before conjugation with polymalic acid (P), starPEG
(PEG200-AHNP)2-PEG-Mal was synthesized using the
N-hydroxysuccinimide (NHS) ester dicyclohexylcarbodiimide
(DCC) method for activation of the starPEG carboxylic
groups.19 Two of the 8 pendant carboxylic groups were amidated
with NH2-PEG200-AHNP resulting in the simple conjugates
used to measure binding to the HER2 protein by surface plasmon
resonance (SPR) and to demonstrate contraction by dynamic
light scattering. Then, after the synthesis of starPEG
(PEG200-AHNP)2, Mal-PEG3400-NH2 was added in the same
reaction mixture. It should be noted, because of conjugation of
the Mal-PEG3400-NH2 linker, the number of sites available for
the attachment of NH2-PEG200-AHNP was 7 per starPEG
molecule. After stripping of the unreacted NHS (pH .8, 100 mM
phosphate) and passage over a PD-10 column (pH .5, 100 mM
phosphate), the purified Mal-PEG3400-starPEG(PEG200-
AHNP)2 was thio-alkylated at the maleinyl residue of “pre-
conjugate” P/LLL(40%)/MEA(10%) (Figure 1), prepared by
amidation of NHS-activated polymalic acid (P) using
(L-leucine)3 (LLL) and 2-mercapto-1-ethylamine (MEA).
19
Note that the percentage indicates the amount of loaded ligand
molecules with regard to the number of malic acid residues per
polymer. Immediately after completion of the reaction, the
remaining sulfhydryl groups of P/LLL(40%)/PEG3400-
starPEG(PEG200-AHNP)2(2%) were conjugated with 3-(2-
pyridyldithio)-propionyl-amido-AON (PDP-AON) to yield
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Figure 1. Synthesis of the lead mini nanodrug P/LLL(40%)/PEG3400-starPEG(PEG200-AHNP)2(2%)/AON(1.5%). The preconjugate and
Mal-PEG3400-starPEG(PEG200-AHNP)2 are synthesized independently before conjugation with PDP-AON and PDP to obtain the lead mini nanodrug.
Star-PEG is an 8-arm branched PEG with terminal carboxylic acids. AHNP refers to the anti-HER2/neu peptide having an exocylic disulfide closed loop. The
indicated percentages refer to the fraction of malic acid residues attached with the indicated ligand. Abbreviations: P, poly(β-L-malic acid); LLL,
leucyl-N-leucyl-N-leucine; Mal, maleimide; PEG200 or PEG3400, polyethylene glycol with molecular weights of 200 or 3400; starPEG, 8-arm PEG carboxylic
acid (−COOH); AHNP, anti-HER2/neu peptide; NHS, N-hydroxysuccinimideester; PDP, 3-(2-pyridyldithio)-propionic acid; AON, antisense oligonucleotide.
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RP/LLL(40%)/PEG3400-starPEG(PEG200-AHNP)2(2%)/AON(1.5%) or with free PDP to yield P/LLL(40%)/
PEG3400-starPEG(PEG200-AHNP)2(2%) (no drug). Then,
additional PDP reagent was added to block any remaining free
sulfhydryl groups. The products were purified over Sephadex
G-75 (pH .4, PBS) and frozen in aliquots at −80 °C until use.
Under the given conditions (i.e., pH, concentrations, reaction
time), maleinyl thiolation and MEA disulfide formation by
reaction with 3(2-pyridyldithio)propionyl-amido-AON or the
PDP reagent were smooth and complete, and sulfhydryl-induced
opening of the AHNP disulfide bridge was not observed. Table 1
summarizes the results for chemical composition and hydrody-
namic properties.163
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169starPEG conjugate tags with Alexa Fluor 680
Conjugate P/LLL(40%)/PEG3400-starPEG(2%)/Alexa(1%)
was synthesized by thiolation of P/LLL(40%)/MEA with
Mal-PEG3400-starPEG and Alexa Fluor 680 C2-Mal.
Conjugate P/PEG3400-star(PEG200-AHNP)2(2%)/Alexa(1%)was synthesized by thio ether formation with Alexa Fluor
680 C2-Mal with PMLA/MEA(10%) and then with
Mal-PEG3400-starPEG(PEG200-AHNP)2. In all syntheses in-
volving thiolation, the unreacted sulfhydryls were blocked with
PDP. All products were purified by sieving over a PD-10
column.Other conjugate tags with Alexa Fluor 680
Conjugates Alexa(1%)/star-PEG(PEG200-AHNP)2-8 were
obtained after NHS activation followed by amidation with
appropriate amounts of NH2-PEG200-AHNP and amino-Alexa
Fluor 680. Excess NHS ester was hydrolyzed in phosphate buffer
(pH .8, 100 mM). Conjugates Alexa(1%)/P/PEG(200)-
AHNP(2%) or Alexa(1%)/P/PEG(2000)-AHNP(2%) and
Alexa(1%)/P/LLL(40%)PEG(200)-AHNP(2%) or Alexa(1%)/
P/LLL(40%)PEG(2000)-AHNP(2%) were similarly prepared
by amidation of NHS-activated PMLA with NH2-PEG200-
AHNP or NH2-PEG2000-AHNP, NH2-LLL, and NH2-Alexa
Fluor 680.
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Table 1t1:1
The composition and hydrodynamic properties of the nanoconjugates.t1:2
t1:3 Nanoconjugates
t1:4 #1† #2‡ #3§ #4||
t1:5 PMLA (kDa) 50 50 50 50
t1:6 Malic acid per injection (μg) 21 12 50 50
t1:7 Loading (%)
t1:8 AHNP analogue 38 2 2 4.6 4.6
t1:9 AON Not loaded 2 Not loaded 1.5
t1:10 Dose (mg/kg)¶
t1:11 AHNP analogue 38 0.4 0.25 1.5 1.5
t1:12 AON 0 1.5 0 2.4
t1:13 Hydrodynamic diameter (nm) 3.3 3.7 7.8 7.8
t1:14 Zetapotential (mV) −6.7 −15.8 −13.8 −14.4
Abbbreviations: PMLA, poly(β-L-malic acid); AHNP, anti-HER2/neu
peptide; AON, antisense oligonucleotide; LLL, leucyl-N-leucyl-N-leucine;
PEG200 or PEG3400, polyethylene glycol with molecular weights of 200 or
3400; starPEG, 8-arm PEG carboxylic acid (−COOH); %, percent loading of
total malic acid content.t1:15
† #1 P/LLL(40%)/PEG200-AHNP(2%).t1:16
‡ #2 P/LLL(40%)//PEG200-AHNP(2%)/AON(1.5%).t1:17
§ #3 P/LLL(40%)/PEG3400-starPEG(PEG200-AHNP)2(2%).t1:18
|| #4 P/LLL(40%)/PEG3400-starPEG(PEG200)-AHNP)2(2%)/AON(1.5%).t1:19
¶ Injected into tumor-bearing mice.t1:20
Table 2 t2:1
Kinetic parameters for AHNP (analogue 38) nanoconjugates binding to
HER2. t2:2
t2:3kon(s
−1 M−1) koff(10
−3 sec−1) Kd(10
−6 M)⁎
t2:4AHNP 800 0.42 0.52
t2:5starPEG(PEG200-AHNP)2 118 0.54 4.6
t2:6starPEG(PEG200-AHNP)4 1.5 0.62 410
t2:7starPEG(PEG200-AHNP)6 Binding not detected
t2:8starPEG(PEG200-AHNP)8 Binding not detected
Abbreviations: AHNP, anti-HER2/neu peptide; HER2, human epidermal
growth factor receptor 2; starPEG, 8-arm PEG carboxylic acid (−COOH);
PEG200, polyethylene glycol with molecular weight 200. t2:9
⁎ Kd = koff/kon. t2:10
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Physico-chemical characterization of conjugates
Synthetic reactions were monitored by thin layer chromatog-
raphy (TLC) using ninhydrin reagents for amidation. Ellman's
reagent was used to follow thiol consumption.21 Reaction
products were tested by SEC-HPLC to verify purity. PMLA
absorbance was followed at a wavelength of 220 nm and was
close to zero at 260 nm (maximum for AONs absorbance) and
280 nm (maximum for peptides containing Tyr, Phe, Trp). A
high-resolu t ion SEC-HPLC column (Phenomenex
Polysep-GFC-P 4000 column, Torrance, CA, USA) was used
in combination with the HPLC Elite LaChrom system L-2130
equipped with a diode array detector L-2455 (Hitachi,
Pleasanton, CA, USA).
In addition, nanoconjugate constituents were assessed by
analyzing malic acid and AON content as previously
described.19 The AHNP peptide content was quantified as
follows: samples and standard peptide, each in 200 μL 6 M HCl
solution, were hydrolyzed at 110 °C for 20 h in a sealed
ampoule. After HCl evaporation and reconstitution, the sample
was added to an aqueous mixture of potassium tetraborate,
o-phthaldialdehyde, and mercaptopropinionic acid and kept for
1 min. After addition of sodium acetate buffer to the sample,
aliquots were injected into the reverse phase column LaChro-
meUltra C18 column (Hitachi) using a gradient mobile phase:
buffer A, 0.05 M sodium acetate (4.1 g/L) with 25 mL of
acetonitrile in 1 L of water (pH .0); buffer B, 0.05 M sodium
acetate in 300 mL of water and 700 mL of methanol. The
amount of peptide was calculated on the basis of the eluted
amino acids of the standard peptide.TE
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Nanoconjugates were characterized with respect to hydrody-
namic diameter and zeta potential using a Malvern Zetasizer
Nano-ZS90 (Malvern Instruments, UK). For the hydrodynamic
diameter measurements (25 °C), the solutions were prepared in
PBS at a concentration of 2 mg/mL and filtered through a 0.2-mm
pore membrane. For the zeta potential measurements, the sample
(1-2 mg/mL) was dissolved in water containing 10 mMNaCl, and
a voltage of 150 mV was applied. Means ± standard deviations
are reported for three independent measurements.
Dissociation constants of HER2-ligand complexes were
measured with the SPR biosensor SensiQ Pioneer (SensiQ,
Oklahoma City, OK, USA) similarly as previously described.8
Recombinant human HER2 (Thr 23 - Thr 652) fused to IgG1 Fc
Tag was produced in human 293 cells (HEK293, catalog #
HE2-H5253; ACROBiosystems, Atlanta, GA, USA). For
immobilization, lyophilized HER2-Fc was reconstituted in
sterile water to a final concentration of 0.1 mg/mL. Immediately
prior to immobilization, 150 μL (25 μg/mL diluted in 10 mM
sodium acetate, pH .5) was flowed over a SensiQ COOH5 chip at
a rate of 10 μL/min using a running buffer of 1× PBS and
0.005% Tween 20. After deactivation using 1 M ethanolamine,
pH .5, the final level of immobilization was determined to be
~6500 resonance units (RUs). To test for binding activity,
100 μL of a solution of trastuzumab (30 nM, 1× PBS, 0.005%
Tween 20) was flowed over the surface at a rate of 20 μL/min.
Immediately after immobilization, the antibody gave an RU level
of ~1500; while after 11 days, it still gave an RU level of ~1050.
AHNP was initially solubilized in 10 mM glycine, pH .5. The
mixture was vortexed and ultra-sonicated to maximize peptide
solubility. Then within 1 min during mixing, an equal volume of
2× PBS and 0.01% Tween 20 was added to give a final
concentration of 1 mg/mL (the resulting pH of the solution was
approximately 8.5). Concentrations of peptides ranging from
156 nM to 10 μM were made using running buffer (1× PBS,
0.005% Tween, and 5 mM glycine, pH .5). Assays were
performed using 700 μL of peptide at a fast flow rate of
25 μL/min at a temperature of 25 °C. The kinetic parameters
were fit by rate constants using the calculation program provided
by SensiQ. Experiments were performed in duplicate. The
surface was regenerated by two 17-μL injections of 1 M NaCl
and 10 mM NaOH at a flow rate of 50 μL/min between
each cycle.
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Figure 2. Dynamic light scattering was used to measure the hydrodynamic
diameters of starPEG conjugates that contained from zero to eight AHNPs
conjugated by amide bonds to the terminal carboxylic groups. (A)
Compaction of the starPEG conjugates as a function of the number of
attached AHNPs is indicated by a shift toward smaller diameters with a larger
number of AHNPs. (B) Proposed hypothesis of intramolecular aggregation
of hydrophobic AHNPs driving the compaction of the starPEG conjugate.
Color codes in panels A and B indicate the number of attached AHNPs.
Abbreviations: starPEG, 8-arm polyethylene glycol (PEG) carboxylic acid
(−COOH); PEG200, polyethylene glycol with molecular weight 200; AHNP,
anti-HER2/neu peptide; n, number of attached AHNPs.
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CMini nanodrug uptake in vitroBT474 cells were trypsinized and maintained as single cells in
Hybri-Care medium. Cells were incubated with 0.1-10 μM Alexa
Fluor 680-stained nanoconjugates for 2 hours at 37 °C. Positive
controls were obtained by incubation with Alexa Fluor 680
conjugated to trastuzumab, while negative controls were not
stained. Cells were washed, fixed with 2% paraformaldehyde, and
run on a Cyan (Beckman Coulter, Brea CA, USA) or BD LSR II
(BD Biosciences, San Jose, CA, USA) flow cytometer. Flowing
Software (version 2.3.3; flow cytometry data analysis software
available for free on the internet) was used for the analysis.301
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Animal experiments were performed in accordance with the
protocols approved by the Cedars-Sinai Medical Center
Institutional Animal Care and Use Committee (IACUC
#4658). Athymic female NCr nude mice, age 8-10 weeks,
(20 g body weight, CrTac:NCr-Foxn1nu homozygous; Taconic,
Hudson, NY, USA) received estrogen pellets (0.72 mg, 90-day
sustained release, Innovative Research of America, Sarasota, FL,
USA) under the skin near the neck. One week after estrogen
pellet placement, mice were inoculated in the flank with 107
BT474 cells re-suspended in Matrigel (Corning Life Sciences,
Corning, NY, USA). Treatment started when tumors had reached
the size of 120 mm3. Per injection, each mouse received 150-μL
test solution.P
R
O
O
F
HER2-positive breast cancer imaging in vivo
Mice with BT474 flank tumors that had reached the size
of 120 mm3 were injected once with the dye-tagged nanoconju-
gates. After 24 hours, mice were euthanized, and various organs
and tumors were imaged using the Xenogen IVIS Imaging
System (PerkinElmer, Waltham, MA, USA) with Living Image
software (Symantec, Mountain View, CA, USA).
HER2-positive breast cancer treatment in vivo
Once BT474 flank tumors reached the size of 120 mm3, the
mice were given 150 μL each injection, twice a week with the
mini nanodrug and P/LLL(40%)/PEG3400-starPEG(PEG200-
AHNP)2 (2%) (no drug). After a total of 8 injections, the animals
were kept under observation for one additional week. Tumor size
was measured using calipers twice a week and calculated as
length × (width2)/2 in mm3.
Statistical analysis
Bars in the figures represent standard errors of the mean. The
P values were calculated using Student's t test, and P b 0.05
was considered significant.E
DResults
Chemical synthesis of peptide nanoconjugates
The design of mini nanoconjugates was based on our
previous success of inhibiting the growth of xenogeneic
BT474 HER2-positive human breast cancer in nude mice.4
Instead of using trastuzumab for active tumor targeting and the
anti-transferrin receptor (anti-TfR) antibody for extravasation,
we designed a mini nanodrug for the same purpose but replaced
trastuzumab and the anti-TfR antibody by AHNP (analogue 38).
Notably, AHNP (analogue 38) has a lower affinity for binding
the HER2 receptor, as indicated by a dissociation constant of
Kd = 0 .15 μM compa red wi t h Kd = 1 .04 nM for
trastuzumab.6,7 In addition, the mini nanodrug was subjected
to the low water solubility of the peptide and the tendency for
aggregation. Other AHNP versions have been reported owing
higher solubility albeit at lower HER2-affinity.8 Kd values in the
micromolar range and limited solubility are not unusual for
rationally designed peptides and challenged us to present
evidence that our concept can circumvent these limitations. We
synthesized AHNP-conjugates with straight linear linkers and
with branched PEG linkers and tested them for binding to the
HER2 protein. While the linear linkers were not successful for
binding to the HER2 receptor, the branched 8-arm starPEG
linker yielded conjugates suitable for tumor targeting as
evidenced by in vivo imaging and subsequent cancer treatment.
The nanoconjugates with or without attached Alexa Fluor 680
were synthesized either with linear PEG-linkers of the type P/
PEG(200-2000)-AHNP(2%-8%) or with branched PEG-linkers
of the type starPEG(PEG200-AHNP)2-8. The percentage (%)
refers to the fraction of ligand-attached malyl residues. The
compounds were synthesized in 70%-80% yield and matched the
designed compounds in composition. The conjugates were
U
N
C
O
R
R
E
C
TE
D
 P
R
O
O
F
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
Figure 3. Mice with BT474 flank tumors that had reached the size of 120 mm3 received IV tail injections of Alexa Fluor 680-labeled P/LLL(40%)/
PEG340-StarPEG(PEG200-AHNP)2(2%), the no drug without AHNP, or with labeled linear PEG conjugates. After 24 hours, imaging of the tumor and organs
was performed. The doses (mg/kg) are marked in red type in both panels. (A) The amount of nanoagent in the tumor is reflected by the fluorescence intensity in
the region of interest. The fluorescence intensity after correction for the background intensity in the same region of an untreated mouse is depicted in the
histogram. (B) The distribution of the lead nanoagent, with and without the targeting AHNP, also indicates uptake in liver and kidneys but minimal uptake in
spleen. Abbreviations: P, poly(β-L-malic acid); LLL, leucyl-N-leucyl-N-leucine; PEG200 or PEG3400, polyethylene glycol with molecular weights of 200 or
3400; starPEG, 8-arm PEG carboxylic acid (−COOH); AHNP, anti-HER2/neu peptide.
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namic properties of representative compounds are summarized in
Table 1. The small size indicated by a hydrodynamic diameter
b10 nm is at the low end of the nanoscale range and justifies the
name “mini nanoconjugates.” The molecular weight calculated
by the design is 210 kDa for the lead nanodrug. The ligation with
AHNP and AON only moderately affected the diameter, but
variation of the linker size in the range of PEG200 toPEG3400-starPEG(PEG200) increased the diameter from
3.3 nm to 7.8 nm.
Flow cytometric measurement of HER2 binding with BT474
cells was not possible because of the loss of bound,
fluorescent-labeled nanoconjugates during cell washing. As an
alternate approach, we followed BT474 cell uptake of peptide
nanoconjugates. Typically, when testing Alexa(1%)/P/
LLL(40%)/PEG200-AHNPn=1, the peak of fluorescent cells
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Figure 4. Growth of HER2-positive BT474 human breast cancer tumors in
mice that received IV tail injections of PBS (red line), the mini nanodrug
(green line; 2.4 mg/kg AON, 1.5 mg/kg AHNP), or the “empty” drug carrier
(blue line; 0 mg/kg AON, 1.5 mg/kg AHNP). Injections were given twice per
week, for a total of 8 injections, and were followed by one week of
observation. Statistical significance was calculated with reference to the PBS
group (P b 0.001 and marked as **). Abbreviations: PBS, phosphate-buf-
fered saline; P, poly(β-L-malic acid); LLL, leucyl-N-leucyl-N-leucine;
PEG200 or PEG3400, polyethylene glycol with molecular weights of 200
or 3400; starPEG, 8-arm PEG carboxylic acid (−COOH); AHNP, anti-HER2/
neu peptide; AON, antisense oligonucleotide.
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shifted by 8%-10% with reference to the shift for trastuzumab.
By raising the number of conjugated AHNP or by increasing the
concentration from 0.025 to 1.0 μM, the shift increased slightly.
However, at higher concentration, the shift reverted and was
tentatively interpreted as AHNP self-aggregation that inactivated
receptor binding and decreased uptake. Similar results were
obtained for the nanoconjugates in which linker PEG200 had
been replaced by the linker PEG2000, suggesting that the
presumed aggregation could not be influenced by an increase in
linker length. For Alexa(1%)/PLLL(40%)/starPEG(PEG200-
AHNP2)2%, similar shifts were observed, however, without
the reversal. We surmised that in this nanoconjugate the
branched PEG-linker resisted aggregation and that it should be
used in further experiments.
Binding of AHNP-nanoconjugates to the HER2 receptor
The affinity of the HER2 protein for binding free AHNP and
AHNP-conjugates was measured by using SPR. Values of the
rate constants for complex formation (kon), complex dissociation
(koff), and the calculated dissociation constant Kd = koff/kon are
summarized in Table 2. While starPEG with maximally 4
conjugated AHNP ligands displayed binding, the conjugates
with 6 and 8 ligands were inactive. Further studies showed that
conjugates with linear PEG-AHNP linkers were all inactive.
Next, we analyzed how the increase in ligation influenced the
binding kinetics. By comparing the binding of free AHNP and
starPEG conjugated with 2 or 4 AHNP ligands, we found that the
rate constant kon decreased, while koff remained essentially
unchanged (Table 2). The decrease in kon resulted in the increase
of Kd, equivalent to a reduction in binding affinity. ConsideringE
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F
the possibility of aggregation, the reduction in kon corresponded
to an increased fraction of aggregated AHNP that was unable to
bind HER2 protein. In fact, the AHNP contained 7 amino acids
with hydrophobic side chains out of 12 total amino acids and
was poorly water soluble.8 We proposed that the observed
decrease in binding affinity was the result of intramolecular
aggregation and peptide inaccessibility, as schematically
depicted in Figure 2.
This hypothesis of intramolecular aggregation was tested by
using dynamic light scattering to determine whether a decrease
of the hydrodynamic diameter occurred due to compaction.
Experimental support for this hypothesis was obtained for
starPEG(PEG200-AHNP)n by varying the number of attached
AHNPs (i.e., n = 0, 2, 4, and 8). As shown in Figure 2, A, as the
number of attached AHNPs was increased, the hydrodynamic
diameter was reduced from 7.5 nm (n = 0) to 3.5 nm (n = 8).
HER2-positive breast cancer imaging analysis
The targeting activity of AHNP was tested by imaging
experiments. The peptide-containing conjugates were attached to
the fluorescent dye Alexa Fluor 680 that reported the uptake and
accumulation in targeted tissue. After IV tail injection, nude mice
with flank tumors derived from HER2-positive BT474 human
breast cancer cells were imaged using the Xenogen IVIS Imaging
System. To improve detection and minimize false–positive
results, tumors were isolated 24 h after injection. The results are
shown in Figure 3, A. The strong fluorescence signal obtained
for P/PEG3400-star(PEG200-AHNP)2(2%)/Alexa(1%) indicat-
ed tumor recognition and uptake and confirmed the binding to
the HER2 receptor seen by the SPR method. The tumor after
injection of P/LLL(40%)/PEG3400-starPEG(2%)/Alexa(1%)
did not accumulate fluorescence, in accord with the absence of
the targeting peptide. Furthermore, the conjugates Alexa(1%)/P/
PEG200 -AHNP(2%) and A l e x a ( 1%) /LLL ( 40%) /
PEG200-AHNP(2%) with linear PEG-linkers were inactive, in
agreement with the absence of HER2 binding noted above in the
SPR experiments. The distribution of fluorescence in the organs
of liver, kidney, spleen, lung, heart, brain, and skin was
measured and is shown in Figure 3, B (24 hours after injection).
The high intensities in liver and kidney but low intensity in
spleen are in agreement with the function of clearance pathways.
Absence of fluorescence in lung, heart, brain, and skin suggests
an absence of major toxic side effects.
Growth inhibition of HER2-positive breast cancer in vivo
Nude mice inoculated with BT474 human breast cancer cells
(HER2-positive) developed flank tumors with a size of
120 mm3. The mice were given IV injections of AHNP
(analogue 38) twice a week, for a total of 8 injections at the
doses indicated in Table 1. The last injection was followed by a
1-week follow-up observation period. Tumor growth after
injection of the no drug nanoconjugate (not containing the
AON) was similar to the tumor growth in mice that received PBS
(control), whereas significant inhibition of tumor growth was
observed after injection of the mini nanodrug (Figure 4). The
tumor size when treated with the lead mini nanodrug remained
unchanged or reduced in size during the first to eight injections,
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Figure 5. Visual appearance of mice after treatment (upper panels) and tumors (lower panels). Mice were euthanized at the end of the experiment (i.e., after
treatment and follow-up observation periods; time points shown in Figure 4). Results are shown for injected PBS (control), no drug nanoconjugate, and mini
nanodrug. Arrows indicate positions of tumors. Abbreviations: n.d., tumor not detectable; PBS, phosphate-buffered saline; P, poly(β-L-malic acid); LLL,
leucyl-N-leucyl-N-leucine; PEG200 or PEG3400, polyethylene glycol with molecular weights of 200 or 3400; starPEG, 8-arm PEG carboxylic acid (−COOH);
AHNP, anti-HER2/neu peptide; AON, antisense oligonucleotide.
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and one week after, treatment was finished in comparison with
the PBS group and the no drug group. The tumor size in the
treatment group was about 15 times smaller (medium size for
treatment group was 120 mm3 versus 1800 mm3 in control
(PBS) group; P b 0.005). The resulting tumor growth in visual
form is shown in Figure 5. Large tumors were seen in the PBS
control group and the no drug group, whereas after treatment
with the lead nanodrug, the tumor was small or not detectable.
The amount of body weight lost during treatment with the mini
nanodrug or with the no drug nanoconjugate was 5%-6% of the
weight for PBS-injected mice.455
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Targeted small nanoconstructs with an elongated shape have
the ability for deep tissue penetration due to hydrodynamic
considerations15,17 and are, therefore, highly promising types of
nanodrugs. Our mini nanodrug consists of PMLA, attached to
several HER2-specific AONs,4 several 12-mer mimetic peptides
that specifically target the HER2 receptor,6–8 and a number of
trileucine residues that manage the escape into the cytoplasm
after endosome uptake into the recipient cell.19 We have
previously shown that the apparent hydrodynamic diameter of
polymalic acid nanoconjugates largely reflects the longitude of
the polymer platform in spite of loading with peptides,
antibodies, and oligonucleotides. 23 This finding has been
explained by the assumption that the hydrodynamic radius
reflects the length of the negatively charged polymer backbone
and that the peptide and oligonucleotide substituents along theTEchain are extended orthogonally to the polymer backbone, andthus, these substituents do not add significantly to the measured
radius. This feature has been directly visualized by transmission
electron microscopy (TEM) for DOTA-gadolinium-polymalic
acid conjugates.5 In our approach, we assumed that such
nanodrugs are ellipsoids with a given ratio of their long to short
axis, where the long axis refers to the polymer backbone. We
estimated an axial ratio of 5:1 on the basis of bond lengths of
atoms in the polymer and substituents. On the basis of these
arguments, it seems appropriate to assume that our mini
nanodrug has an elongated shape.
The anti-HER2 mimetic peptide contains an exocyclic
disulfide bridge that formed spontaneously during sulfhydryl
oxidation in air.8 Furthermore, this exocyclic structure stabilizes
the peptide against degradation in the blood after IV injection.22
However, the relatively high proportion of hydrophobic side
chains of AHNP (analogue 38) posed the problem of
spontaneous self-aggregation and compaction of the
AHNP-starPEG conjugate that became evident at higher than
micromolar concentrations of the nanoconjugates. After aggre-
gation, the AHNP residues did not bind HER2 protein. Results of
SPR-binding studies and in vivo imaging experiments suggest
that branched PEG linkers such as in starPEG, and in contrast to
linear PEG linkers, can improve the binding of polymalic
acid-conjugated hydrophobic AHNP. This experimental ap-
proach using branched PEG as linker for hydrophobic peptides
could be useful in general.
Although the binding for starPEG(PEG200-AHNP)n (n = 2)
(Table 2) is moderate according to SRP experiments, targeted
delivery by AHNP conjugates could turn out to successfully
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block HER2 signaling in vivo if the dissociation rate of the
HER2-AHNP conjugate complex is slow (i.e., koff for AHNP is
comparable to koff for trastuzumab).
8 Kinetically, blocking could
be achieved if the rate of dissociation was slower than the rate of
receptor internalization (24 and references therein). Moreover, it
cannot be ruled out that self-masking of AHNP by aggregation
might be partially reversed as a result of interaction, for example
with serum constituents, allowing increased peptide access of the
receptor and binding affinity and even the possibility of
oligovalency for receptor binding.
The results of tumor growth inhibition compared favorably
with those of our previously reported results for nanodrugs of a
similar design that involved trastuzumab, which has high affinity
binding for the HER2 target.4,5 In those previous studies,
trastuzumab itself caused a substantial degree of inhibition due to
blocking of the HER2 signaling pathway.4 In our current study,
however, the attached AHNP in the no drug nanoconjugate
(Figure 4) did not give rise to detectable growth inhibition (dose
of 1.5 mg/kg). Similarly, only a modest degree of inhibition was
reported for free AHNP (dose of 4 mg/kg).12 That the observed,
significant inhibition could have been caused by AON itself and
not involve HER2-targeted cell uptake (dose of 1.5 mg/kg) is
unlikely because AON in the absence of HER2 targeting at an
even higher dose of 2.5 mg/kg inhibited tumor growth by only
30%-40%.4 The degree of inhibition by our lead mini nanodrug
(containing starPEG-AHNP, Figure 4) was spectacular and
compared well with the previously reported degree of inhibition
by our nanoconjugates that contained trastuzumab.4,5 We think
that this increased inhibition resulted from the superior tumor
penetration of the mini nanodrug, because of a faster and deeper
diffusion. The favorable delivery profile, the biodegradability,
and the demonstrated absence of toxicity among Polycefin
nanodrugs4 are beneficial assets of the mini nanodrug, which
might be successfully used in the future for treating HER2-
positive breast cancer.
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